Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM's stock surged 36.79% after promising DURIPANC Phase 2 study updates. The study evaluates Ampligen with AstraZeneca's Imfinzi for pancreatic cancer. Early results show 64% overall survival surpassing expectations in this cohort. AIM obtained a U.S. patent for Ampligen as an oncology treatment until 2039. Combination therapies are gaining traction among biotechnology firms for hard-to-treat cancers.
View signal analysis